[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

FirstWord: Market Research Reports

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:

  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.


FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Publications found: 700
Sort by:

Riding the Wearable Trend: Opportunities for Pharma

US$ 695.00

Riding the Wearables Trend: Opportunities for Pharma Wearable health technology ... potential? Riding the Wearables Trend: Opportunities for Pharma investigates the potential for wearable devices, ... the expertise of outsiders to successfully adapt to the wearable trend, or create new internal roles and functions? ...

September 2017

The Future of Market Access in Europe

US$ 2,245.00

... price harmonisation Will Brexit disrupt EU market access to medicines? Evolving market-access challenges and remedies in Europe ... market access Where market-access policies are heading at national level Key insights Variation and consistency in market-access factors at national level Traditional market-access ...

September 2017

The Future of Market Access in US

US$ 2,245.00

... nature of FDA not viewed as a hindrance to market access Drugmaker response and market access Key insights RWD could prove helpful in making formulary ... not expected to alter market access The US political climate and market access Key insights Obamacare has had mixed impact on market access, but repeal brings ...

September 2017

Value Added Services in Cardiometabolic Diseases -- Payer views

US$ 2,245.00

... value-added services? The role of value-added services in cardiometabolic diseases Key insights on the role of value-added services in cardiometabolic diseases The challenge of behavioural change Do VAS influence pricing & reimbursement decisions? Types of value-added services ...

September 2017

Harnessing Patient-Centricity to Drive Profitability

US$ 695.00

... success look like? And can patient-centric performance be accurately measured or compared? Harnessing Patient Centricity to Drive Profitability takes a pragmatic view across the patient-centric landscape, drawing upon the ...

September 2017

Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

US$ 695.00

... set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the ... the pricing, reimbursement and HTA status of each product at the national level Profile the therapy areas that are being targeted by innovative drugs ...

September 2017

NPS+ Type 2 Diabetes Mellitus [2017] EU5

US$ 2,575.00

... does each of the leading brands compare to its competitors? NPS+ Type 2 Diabetes Mellitus (EU5) gives a unique insight into the overall brand health ... degludec/liraglutide; Novo Nordisk) Explore Important Brand Loyalty Issues NPS+ Type 2 Diabetes Mellitus (EU5) offers valuable insight into brand loyalty from ...

August 2017

NPS+ Type 2 Diabetes Mellitus [2017] US

US$ 2,575.00

... how does each of the leading brands compare to its competitors? NPS+ Type 2 Diabetes Mellitus (US) gives a unique insight into the overall brand health of ... (liraglutide; Novo Nordisk) Explore Important Brand Loyalty Issues NPS+ Type 2 Diabetes Mellitus (US) offers valuable insight into brand loyalty from the ...

August 2017

Atopic Dermatitis [2017]

US$ 8,145.00

... targeted treatments look set to transform the treatment of moderate to severe atopic dermatitis. As Dupixent (dupilumab; Regeneron/Sanofi) gains traction, older, more ... dupilumab might become a kind of blockbuster drug for the treatment of atopic dermatitis from the data which are available now.” European Key ...

August 2017

Colorectal Cancer [2017]

US$ 8,145.00

... multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol ... You should move to another target or modify something. I have worked on colorectal cancer for 15 years more or less. I have never seen any Phase ...

August 2017

Key Success Factors in Pricing, Reimbursement and Market Access

US$ 695.00

... pharma companies renew or upgrade their commercialisation strategies? Key Success Factors in Pricing, Reimbursement and Market Access investigates innovative pharma- ... business now and in the future? What are the key success factors in pricing, reimbursement, and market access contracting? Table of Contents ...

August 2017

Market Access Impact (EU5) [Cancer Pain]

US$ 5,145.00

... your brand, and whether market barriers are dragging your market share down, in Market Access Impact: Cancer Pain (EU5). Based on a survey ... PecFent (fentanyl intranasal; Kyowa Kirin) Exploring Market Access Barriers Market Access Impact: Cancer Pain (EU5) explores key issues affecting drug manufacturers. You ...

August 2017

Market Access Impact (EU5) [Myeloma]

US$ 5,145.00

... ; Celgene) Thalidomide (thalidomide; Celgene) Velcade (bortezomib; Takeda) Exploring Market Access Barriers Market Access Impact: Multiple Myeloma (EU5) explores key issues affecting drug manufacturers. You’ll learn ...

August 2017

Market Access Impact (US) [Cancer Pain]

US$ 5,145.00

... Subsys (fentanyl sublingual; Insys Therapeutics) Exploring Market Access Barriers Market Access Impact: Cancer Pain (US) explores key issues affecting drug ... Subsys (fentanyl sublingual; Insys Therapeutics) Exploring Market Access Barriers Market Access Impact: Cancer Pain (US) explores key issues affecting drug ...

August 2017

Market Access Impact (US) [Myeloma]

US$ 5,145.00

... and what you can do to win it back, in Market Access Impact: Multiple Myeloma (US). Based on a survey of 100 medical oncologists and ... ; Celgene) Velcade (bortezomib; Takeda) Exploring Market Access Barriers Market Access Impact: Multiple Myeloma (US) explores key issues affecting drug manufacturers. ...

August 2017

Medical Affairs Reputations (EU5) [Asthma/COPD]

US$ 6,175.00

... and primary care physicians across the EU5 (UK, France, Germany, Italy and Spain) the performance of asthma/COPD medical affairs teams still has a way to go ... see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Asthma/COPD 2017 (EU5) to discover how your team can better meet the high ...

August 2017

Medical Affairs Reputations (US) [Asthma/COPD]

US$ 6,175.00

... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Asthma/COPD 2017 (US) to discover how your team can better meet the ...

August 2017

Multiple Myeloma [2017]: Bulletin #1

US$ 1,045.00

... of haematopoietic stem cells for autologous transplantation in patients with multiple myeloma; Cellectar Biosciences’ announcement of encouraging results from Phase I ... trial investigating CLR 131 in patients with relapsed/refractory multiple myeloma. Business Questions: How does Johnson & Johnson’s and ...

August 2017

NPS+ (EU5) [CLL]

US$ 2,575.00

... how does each of the leading brands compare to its competitors? NPS+ CLL (EU5) gives a unique insight into the overall brand health of 6 leading ... ; AbbVie) Zydelig (idelalisib; Gilead) Explore Important Brand Loyalty Issues NPS+ CLL (EU5) offers valuable insight into brand loyalty from the perspective ...

August 2017

NPS+ (US) [CLL]

US$ 2,575.00

... each of the leading brands compare to its competitors? NPS+ CLL (US) gives a unique insight into the overall brand ... ; Gilead) Explore Important Brand Loyalty Issues NPS+ CLL (US) offers valuable insight into brand loyalty ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

August 2017

RCC [2017]: Bulletin #1

US$ 1,045.00

... , versus Sutent in patients with previously untreated, advanced or metastatic RCC; Exelixis’ filing for US FDA approval of Cabometyx for the ... combination regimens in patients with previously untreated advanced or metastatic RCC? What other barriers to standard practice will Opdivo/ipilimumab/Cabometyx ...

August 2017

Rheumatoid Arthritis [2017]: Bulletin #2

US$ 1,045.00

... have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson announcing the ...

August 2017

The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

US$ 2,245.00

... needed to foster an environment which incentivises the use of biosimilars. The US biosimilars market is just beginning to evolve towards maturity but ... Global Biologics, Mylan, US Cheryl Schwartz, General Manager, US Biosimilars, Pfizer, US Anonymous expert, with extensive regulatory and medical affairs ...

August 2017

Type 2 Diabetes Mellitus [2017]

US$ 8,145.00

Will novel therapies transform the treatment of type 2 diabetes? The treatment of type 2 diabetes mellitus has evolved in recent years with introduction of new classes ... to succeed? Learn how KOLs see the type 2 diabetes market evolving in KOL Insight: Type 2 Diabetes. Twelve US and European KOLs provide candid ...

August 2017

Ulcerative Colitis [2017]

US$ 8,145.00

... approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment landscape. While Pfizer’s JAK inhibitor clearly has a head ... such as anti-TNFs and Takeda’s Entyvio (vedolizumab), in KOL Insight: Ulcerative Colitis. Twelve North American and European KOLs provide their insight ...

August 2017

Adherence – What Do Pharma Really Know

US$ 695.00

Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity ... as they are intended to be taken and reap the benefits accordingly? Adherence: What do pharma really know? explores the main issues including physician impact ...

July 2017

AML [2017]: Bulletin #2

US$ 1,045.00

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics ... to recommend the approval of Pfizer’s Mylotarg in previously untreated, de novo AML patients? To what extent is the ALFA-0701 trial considered compelling ...

July 2017

Bladder Cancer [2017]

US$ 8,145.00

... to differentiate their marketed and pipeline therapies in KOL Insight: Bladder Cancer. Twelve US and European KOLs provide their candid insights on ... how do KOLs view Cyramza (ramucirumab) as a potential treatment for bladder cancer? What will be critical for commercial success in this indication? Which ...

July 2017

Breast Cancer [2017]: Bulletin #1

US$ 1,045.00

... events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from ...

July 2017

CLL [2017]

US$ 8,145.00

... to differentiate their pipeline therapies in KOL Insight: Chronic Lymphocytic Leukaemia (CLL). Twelve US and European KOLs provide their candid insights on seven ... oral targeted drugs? How will Imbruvica’s role evolve in treatment of CLL? Following expanded approval of Janssen/AbbVie’s Imbruvica to first-line ...

July 2017

Cystic Fibrosis [2017]: Bulletin #2

US$ 1,045.00

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; ... ) which were presented at the 40th European Cystic Fibrosis Society Conference in Seville, Spain in June 2017; and Verona Pharma initiating a Phase II ...

July 2017

HNSCC [2017]: Bulletin #2

US$ 1,045.00

... with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced ... that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC ... potential combination treatment regimens for HNSCC? How do KOLs interpret the ...

July 2017

Market Access Impact (EU5) [NSCLC]

US$ 5,145.00

... narrow, but significant lead. Get the details in Market Access Impact: NSCLC (EU5). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (EU5) explores key issues affecting drug manufacturers. You’ll ...

July 2017

Market Access Impact (US) [NSCLC]

US$ 5,145.00

... to overtake their closest rivals. Get the details in Market Access Impact: NSCLC (US). You’ll see how widely prescribed your brand is, ... Pfizer/Merck Group) Zykadia (ceritinib; Novartis) Exploring Market Access Barriers Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. You’ll ...

July 2017

Medical Affairs Reputations (EU5) [CLL]

US$ 6,175.00

... more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (EU5) to discover how your team can better meet ... What specifically are they asking for? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis/Genmab) Gazyvaro (obinutuzumab ...

July 2017

Medical Affairs Reputations (EU5) [Growth Hormone Deficiency]

US$ 6,175.00

... down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, ... doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring, Merck ...

July 2017

Medical Affairs Reputations (US) [CLL]

US$ 6,175.00

... want to see more of; and why some are dissatisfied. Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (US) to discover how your team can ... Could addressing these tip the balance? Insight into Medical Affairs Teams for These CLL Brands Arzerra (ofatumumab; Novartis) Gazyva (obinutuzumab; Roche ...

July 2017

Medical Affairs Reputations (US) [Growth Hormone Deficiency]

US$ 6,175.00

... doctors down Our latest survey shows that while medical affairs teams for growth hormone brands in the EU5 countries (France, Germany, Italy ... with doctors, and get a leg up on the competition, in Medical Affairs Reputations: GHD (EU5). Comparing 7 major growth hormone brands from Eli Lilly, Ipsen, Ferring ...

July 2017

Melanoma [2016]: Bulletin #3

US$ 1,045.00

... the arrival of Array BioPharma’s binimetinib/encorafenib combination to the melanoma treatment landscape? How does Array’s binimetinib/encorafenib compare to Novartis ... give way to Imlygic/Keytruda? What do KOLs think? Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement ...

July 2017

Multiple Sclerosis [2016]: Bulletin #3

US$ 1,045.00

... ) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche reporting that a German ... of Mavenclad (cladribine) for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity, and presenting new ...

July 2017

NASH [2017]: Bulletin #1

US$ 1,045.00

... shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the ... of acetyl-CoA carboxylase (ACC), in patients with NASH. Business Questions: How do KOLs view the positive ... GS-0976 at EASL 2017, and are they hopeful about the therapy in NASH? Are the experts ...

July 2017

NPS+ (EU5) [Haemophilia A]

US$ 2,575.00

... for improvement. Find out what they are in FirstView’s NPS+ Haemophilia A 2017 (EU5). You’ll learn how doctors rated your brand, get insight ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...

July 2017

NPS+ (EU5) [Haemophilia B]

US$ 2,575.00

... score in FirstView’s NPS+ Haemophilia B 2017 (EU5). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (EU5) explores key issues affecting brand loyalty for drug ...

July 2017

NPS+ (EU5) [RA]

US$ 2,575.00

... Spain, Germany, Italy and the UK. NPS+ Rheumatoid Arthritis (EU5) provides clear insight into the results, giving ... . Explore Important Brand Loyalty Issues NPS+ Rheumatoid Arthritis (EU5) gives you clear and independent ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

July 2017

NPS+ (US) [Haemophilia A]

US$ 2,575.00

... satisfaction score in FirstView’s NPS+ Haemophilia A 2017 (US). Building on the respected net promoter score (NPS), the report compares nine major haemophilia A drugs, and ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia A 2017 (US) explores key issues affecting brand loyalty for ...

July 2017

NPS+ (US) [Haemophilia B]

US$ 2,575.00

... score in FirstView’s NPS+ Haemophilia B 2017 (US). Building on the respected net promoter score (NPS), the report compares six major haemophilia drugs, and shows ... 1st and 22nd, 2017. Explore Important Brand Loyalty Issues NPS+ Haemophilia B 2017 (US) explores key issues affecting brand loyalty for ...

July 2017

NPS+ (US) [RA]

US$ 2,575.00

... You Need to Grow. How does NPS work? NPS measures overall brand satisfaction and loyalty ... , 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5. NPS can range from -100 (everybody is a Detractor) to + ... the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into ...

July 2017

NSCLC [2017]

US$ 8,145.00

How will immunotherapy combination regimens impact the NSCLC treatment landscape? The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy ... approvals, could shake up the treatment algorithm for ALK-positive NSCLC, as well as developments in EGFR-, BRAF- and ROS1-positive disease ...

July 2017

Payer attitudes to Orphan Drug pricing

US$ 2,245.00

Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached ...

July 2017

Payer Insights: RA [2016]: Bulletin #3

US$ 1,045.00

... to alter the RA treatment algorithm? What level of discount do payers demand in order to facilitate market penetration of biosimilar adalimumab? How ... RA? What factors will drive the acceptance of biosimilars by payers? How will payers manage the use of biosimilars in treatment-naïve and treatment-experienced ...

July 2017

Filters

Search

Categories

1
43
3
2
3
2
1
16
1
1
8
2
4
1
19
1
1
1
2
31
6
24
62
10
455

Publishers

700

Regions

2
1
15
1
1
14
4
1
660
1

Price

Date

Pages

Offers